Overview

The Practical Evidence of Antidiabetic Combination Therapy in Korea

Status:
Completed
Trial end date:
2019-01-28
Target enrollment:
Participant gender:
Summary
This study evaluate the efficacy and safety of alogliptin and pioglitazone combination therapy in comparison with either alogliptin or pioglitazone on glucose control in the metformin-treated type 2 diabetic patients in Korea.
Phase:
Phase 4
Details
Lead Sponsor:
Kun-Ho Yoon
Collaborator:
Takeda
Treatments:
Alogliptin
Metformin
Pioglitazone